Literature DB >> 23796931

In Vitro Activity of Retapamulin against Staphylococcus aureus Resistant to Various Antimicrobial Agents.

Louis D Saravolatz1, Joan Pawlak2, Stephanie N Saravolatz2, Leonard B Johnson2.   

Abstract

Retapamulin and six other antimicrobial agents were evaluated against 155 methicillin-resistant Staphylococcus aureus (MRSA) isolates, including strains resistant to vancomycin, linezolid, daptomycin, and mupirocin by microdilution tests. Time-kill assays were performed against representative MRSA, vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant S. aureus (VRSA) isolates. Retapamulin and mupirocin demonstrated MIC90s of 0.12 μg/ml and 8 μg/ml, respectively, with resistance seen in 2.6% and 10% of isolates, respectively. Retapamulin maintained good activity against 94% (15/16) of mupirocin-resistant isolates.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Entities:  

Year:  2013        PMID： 23796931      PMCID： PMC3754297          DOI： 10.1128/AAC.00282-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Tatiana Bogdanovich; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W Scott Champney; Ward K Rodgers
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

3.  In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.

Authors:  F J Candel; G Morales; J J Picazo
Journal:  Rev Esp Quimioter       Date:  2011-09       Impact factor: 1.553

4.  Modelling time-kill studies to discern the pharmacodynamics of meropenem.

Authors:  Vincent H Tam; Amy N Schilling; Michael Nikolaou
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

5.  Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; David J Farrell; Teresa Spanu; Giovanni Fadda; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2010-09-14       Impact factor: 5.790

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

Review 7.  Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis?

Authors:  M N Moody; L K Morrison; S K Tyring
Journal:  Skin Therapy Lett       Date:  2010-01

8.  Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent.

Authors:  Maria M Traczewski; Steven D Brown
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191
  8 in total
  7 in total

Review 1.  Prevention of Recurrent Staphylococcal Skin Infections.

Authors:  C Buddy Creech; Duha N Al-Zubeidi; Stephanie A Fritz
Journal:  Infect Dis Clin North Am       Date:  2015-09       Impact factor: 5.982

Review 2.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Decreased susceptibilities to Retapamulin, Mupirocin, and Chlorhexidine among Staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children.

Authors:  J Chase McNeil; Kristina G Hulten; Sheldon L Kaplan; Edward O Mason
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

4.  Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins.

Authors:  Feifei Sun; Huiyan Zhang; Gerard Bryan Gonzales; Jinhui Zhou; Yi Li; Jinzhen Zhang; Yue Jin; Zhanhui Wang; Yanshen Li; Xingyuan Cao; Suxia Zhang; Shupeng Yang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  In Vitro Antimicrobial Activities of Fusidic Acid and Retapamulin against Mupirocin- and Methicillin-Resistant Staphylococcus aureus.

Authors:  Sang Hyun Park; Jin Kyung Kim; Kun Park
Journal:  Ann Dermatol       Date:  2015-10-02       Impact factor: 1.444

6.  Prevalence and molecular characterization of methicillin-resistant Staphylococcus aureus with mupirocin, fusidic acid and/or retapamulin resistance.

Authors:  Wenjing Chen; Chunyan He; Han Yang; Wen Shu; Zelin Cui; Rong Tang; Chuanling Zhang; Qingzhong Liu
Journal:  BMC Microbiol       Date:  2020-06-29       Impact factor: 3.605

7.  Sal-type ABC-F proteins: intrinsic and common mediators of pleuromutilin resistance by target protection in staphylococci.

Authors:  Merianne Mohamad; David Nicholson; Chayan Kumar Saha; Vasili Hauryliuk; Thomas A Edwards; Gemma C Atkinson; Neil A Ranson; Alex J O'Neill
Journal:  Nucleic Acids Res       Date:  2022-02-28       Impact factor: 16.971
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.